RAB9A

Migration, Crosslink

📖

RAB9A

active

wiki page Created: 2026-04-02T07:19:30 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-rab9a

📖 Wiki Page

gene3229 wordssynced 2026-04-02

RAB9A

<div class="infobox infobox-gene">
<div class="infobox-header">RAB9A</div>
<div class="infobox-content">
<div class="infobox-row"><strong>Full Name:</strong> RAB GTPase 9A</div>
<div class="infobox-row"><strong>Symbol:</strong> RAB9A</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> Xp22.33</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 10184</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000123595</div>
<div class="infobox-row"><strong>UniProt ID:</strong> P51153</div>
<div class="infobox-row"><strong>Protein Length:</strong> 201 amino acids</div>
<div class="infobox-row"><strong>Molecular Weight:</strong> ~23 kDa</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Parkinson's Disease, Alzheimer's Disease, Lysosomal Storage Disorders, Niemann-Pick Disease</div>
</div>
</div>

Overview

...

RAB9A

<div class="infobox infobox-gene">
<div class="infobox-header">RAB9A</div>
<div class="infobox-content">
<div class="infobox-row"><strong>Full Name:</strong> RAB GTPase 9A</div>
<div class="infobox-row"><strong>Symbol:</strong> RAB9A</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> Xp22.33</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 10184</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000123595</div>
<div class="infobox-row"><strong>UniProt ID:</strong> P51153</div>
<div class="infobox-row"><strong>Protein Length:</strong> 201 amino acids</div>
<div class="infobox-row"><strong>Molecular Weight:</strong> ~23 kDa</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Parkinson's Disease, Alzheimer's Disease, Lysosomal Storage Disorders, Niemann-Pick Disease</div>
</div>
</div>

Overview

RAB9A (RAB GTPase 9A) is a member of the RAB GTPase family that functions as a molecular switch controlling intracellular membrane trafficking. RAB9A is primarily involved in late endosomal trafficking and lysosomal function, facilitating the transport of mannose-6-phosphate receptors (MPRs) between the trans-Golgi network and late endosomes, a critical pathway for delivery of hydrolytic enzymes to lysosomes.[@lombardi1995] The RAB9A protein is ubiquitously expressed with high levels in brain, particularly in [neurons](/entities/neurons), where it plays essential roles in maintaining lysosomal biogenesis, autophagic flux, and clearance of protein aggregates.[@sano2019] In neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), RAB9A dysfunction contributes to impaired lysosomal trafficking, accumulation of autophagic vacuoles, and failure to clear pathogenic protein aggregates such as [amyloid-beta](/proteins/amyloid-beta), tau, and [alpha-synuclein](/proteins/alpha-synuclein).[@dehay2012] RAB9A belongs to the Rab family of small GTPases that cycle between an active GTP-bound state and an inactive GDP-bound state, with this cycling precisely regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) [1][2].

Function

Membrane Trafficking Regulation

RAB9A functions as a key regulator of late endosomal trafficking pathways:

GTP/GDP Cycle: Like all RAB GTPases, RAB9A switches between active and inactive states:

Active state (RAB9A-GTP): Membrane-associated, recruits effector proteins
Inactive state (RAB9A-GDP): Cytosolic, available for recycling to membranes

This cycle is regulated by:

GEFs: Promote GDP release and GTP binding (activation)
GAPs: Accelerate GTP hydrolysis (inactivation)
GDIs: Extract GDP-bound RAB from membranes

Mermaid diagram (expand to render)

Mannose-6-Phosphate Receptor Trafficking

RAB9A plays a central role in the mannose-6-phosphate receptor (MPR) cycle:

Cargo Recognition: MPRs in the trans-Golgi network bind newly synthesized hydrolytic enzymes bearing mannose-6-phosphate tags

Transport: RAB9A-GTP recruits cargo-containing MPR vesicles

Delivery: Vesicles traffic to late endosomes

Unloading: Enzymes are released in the acidic environment of late endosomes

Recycling: Empty MPRs are returned to the Golgi via RAB9A-mediated transport

This pathway is essential for lysosomal enzyme delivery and cellular degradation capacity.

Lysosomal Function

RAB9A regulates multiple aspects of lysosomal biology:

Lysosomal biogenesis: Delivery of newly synthesized lysosomal enzymes
Lysosomal positioning: Movement of lysosomes within cells
Lysosomal fusion: Fusion of late endosomes with lysosomes
Lysosomal pH maintenance: Indirect regulation through enzyme delivery

Autophagy

RAB9A intersects with autophagy at multiple points:

Autophagosome-lysosome fusion: RAB9A regulates the final fusion step
Late endosome maturation: Converts late endosomes into autolysosomes
Cargo delivery: Transfers autophagic cargo to degradative compartments

Molecular Mechanism and Regulation

The RAB9A protein undergoes a tightly regulated GTPase cycle that controls its activity and localization within cells:

Switch I region (residues 35-50): Conformationally sensitive to nucleotide state, undergoes major restructuring between GTP and GDP-bound forms

Switch II region (residues 67-80): Critical for effector interactions and GAP recognition

GTPase domain: The core catalytic domain that hydrolyzes GTP to GDP

Hypervariable C-terminal region: Contains the CAAX motif for prenylation and membrane targeting

The GTP hydrolysis rate of RAB9A is intrinsically slow but is dramatically accelerated by GAPs. Conversely, GEFs catalyze nucleotide exchange, promoting the active GTP-bound state.

RAB9A GEFs (Guanine Nucleotide Exchange Factors):

p14 (MAP3K14) was originally identified as a RAB9A GEF
Recent evidence suggests additional GEFs may regulate RAB9A in neuronal contexts

RAB9A GAPs (GTPase-Activating Proteins):

TBC1D5 has been implicated as a RAB9A GAP
Retromer complex components modulate RAB9A activity indirectly

RAB9A GDIs (GDP Dissociation Inhibitors):

GDI1 and GDI2 extract RAB9A-GDP from membranes
GDI-mediated extraction enables recycling of RAB9A to donor compartments

Post-Translational Modifications

RAB9A activity is regulated by several post-translational modifications:

Phosphorylation

Casein kinase phosphorylation regulates RAB9A effector interactions
MAPK-mediated phosphorylation affects subcellular localization
PI3K-dependent phosphorylation influences membrane association

Geranylgeranylation

C-terminal CAAX motif undergoes geranylgeranylation for membrane anchoring
Proper prenylation is essential for RAB9A function
Inhibitors of prenylation affect RAB9A trafficking

Ubiquitination

RAB9A can be ubiquitinated, affecting its stability
Lys63-linked ubiquitination may regulate effector recruitment
Proteasomal degradation regulates RAB9A turnover

RAB9A Effector Proteins

RAB9A recruits multiple effector proteins to facilitate cargo transport:

| Effector | Function | Neuronal Relevance |
|----------|----------|-------------------|
| FYCO1 | Autophagosome-lysosome fusion | Clearance of protein aggregates |
| PtdIns3P kinases | Late endosome positioning | Lysosomal function |
| SNX proteins | Membrane remodeling | Endosomal sorting |
| LAMP proteins | Lysosomal membrane proteins | Lysosomal integrity |

Expression

Tissue Distribution

RAB9A is ubiquitously expressed with notable enrichment in neural tissue:

| Tissue | Expression Level |
|--------|-----------------|
| Brain (cerebral cortex) | Very High |
| Brain (hippocampus) | Very High |
| Brain (cerebellum) | High |
| Brain (basal ganglia) | High |
| Brain (substantia nigra) | High |
| Heart | Moderate-High |
| Liver | Moderate |
| Kidney | Moderate |
| Lung | Moderate |
| Spleen | Moderate |

Subcellular Localization

In neurons, RAB9A localizes to:

Late endosomes: Primary compartment for RAB9A function
Trans-Golgi network: Site of MPR loading
Lysosomes: Target compartment for trafficking
Autophagosomes: Involved in autophagy

Disease Associations

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), RAB9A dysfunction contributes to:

Alpha-Synuclein Clearance: The autophagy-lysosome pathway is critical for clearing [alpha-synuclein](/proteins/alpha-synuclein) aggregates. RAB9A regulates lysosomal function, and impaired function leads to [alpha-synuclein](/proteins/alpha-synuclein) accumulation [3].

Lysosomal Dysfunction: PD is associated with lysosomal impairment, particularly in dopaminergic neurons. RAB9A-mediated lysosomal trafficking is essential for neuronal survival.

GBA Interaction: GBA (glucocerebrosidase) mutations increase PD risk, and GBA functions in lysosomal pathways that intersect with RAB9A regulation.

LRRK2 Pathway: LRRK2 regulates membrane trafficking, and RAB9A may intersect with LRRK2 signaling in PD pathogenesis.

Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers-disease):

Lysosomal Dysfunction: Progressive lysosomal failure is a hallmark of AD. RAB9A dysfunction contributes to impaired lysosomal biogenesis and function [4].

Amyloid Clearance: RAB9A-mediated lysosomal trafficking is involved in amyloid clearance. Reduced RAB9A function may impair Aβ degradation.

Tau Pathology: Autophagy-lysosome pathways are important for tau clearance. RAB9A dysfunction may contribute to tau accumulation.

Autophagic Vacuoles: AD neurons accumulate autophagic vacuoles, suggesting impaired flux through the autolysosomal system where RAB9A plays a role.

Lysosomal Storage Disorders

RAB9A intersects with multiple lysosomal storage disorders:

Niemann-Pick Disease: RAB9A function affects cholesterol trafficking through late endosomes.

Mucolipidosis: RAB9A-mediated MPR trafficking is essential for proper lysosomal enzyme targeting.

Sphingolipidoses: RAB9A regulates delivery of hydrolases to lysosomes where sphingolipids are degraded.

Neurodegeneration

General mechanisms by which RAB9A dysfunction contributes to neurodegeneration:

Impaired protein clearance: Failure to degrade aggregate-prone proteins

Lysosomal failure: Accumulation of undegraded material

Mitochondrial dysfunction: Impaired mitophagy

Synaptic dysfunction: Altered trafficking of synaptic components

RAB9A in Parkinson's Disease Pathogenesis

The intersection between RAB9A and Parkinson's disease involves several key molecular pathways:

GBA- RAB9A Axis: Glucocerebrosidase (GBA) mutations represent the most significant genetic risk factor for sporadic PD. GBA functions within the lysosomal compartment where RAB9A-mediated trafficking delivers hydrolytic enzymes. Loss of GBA function leads to glucosylceramide accumulation, which disrupts lysosomal membrane integrity and impairs autophagic flux. RAB9A dysfunction compounds this problem by further reducing lysosomal enzyme delivery, creating a vicious cycle of lysosomal failure and alpha-synuclein accumulation.

LRRK2 Interaction: LRRK2 (leucine-rich repeat kinase 2) mutations cause familial PD and regulate multiple aspects of membrane trafficking. LRRK2 phosphorylates several RAB proteins including RAB29, RAB32, and RAB38, but its relationship with RAB9A remains under investigation. Evidence suggests that LRRK2 dysfunction may indirectly affect RAB9A function through broader trafficking pathway disruption.

Endolysosomal Trafficking Defects: Early PD pathogenesis involves prominent endolysosomal dysfunction. RAB9A plays a critical role in late endosome to lysosome trafficking, and impaired RAB9A function contributes to:

Accumulation of enlarged late endosomes
Impaired autophagosome-lysosome fusion
Defective mitophagy leading to mitochondrial dysfunction
Synaptic trafficking defects in dopaminergic neurons

RAB9A in Alzheimer's Disease Pathogenesis

Amyloid-beta Processing: The autophagy-lysosome pathway is critical for clearing extracellular amyloid-beta and intracellular Aβ aggregates. RAB9A-mediated trafficking delivers lysosomal enzymes to degrade Aβ. Impaired RAB9A function leads to:

Reduced lysosomal degradation of Aβ peptides
Accumulation of Aβ in autophagic vacuoles
Secretion of Aβ via exosome pathways
Enhanced plaque formation in brain parenchyma

Tau Metabolism: Tau protein is degraded through both autophagy-lysosome and proteasome pathways. RAB9A dysfunction impairs lysosomal tau clearance, contributing to:

Accumulation of hyperphosphorylated tau in neurons
Formation of neurofibrillary tangles
Spreading of tau pathology through neuronal connections

Lysosomal Membrane Permeabilization: In AD, lysosomal membrane permeability increases with disease progression. RAB9A dysfunction contributes to lysosomal fragility through:

Impaired delivery of lysosomal membrane proteins
Reduced lysosomal enzyme activity
Accumulation of lipofuscin and other undegraded materials

RAB9A in Amyotrophic Lateral Sclerosis

Emerging evidence links RAB9A to ALS pathogenesis:

TDP-43 Proteinopathy: TDP-43 aggregates characterize most ALS cases. Autophagy-lysosome pathways are critical for TDP-43 clearance, and RAB9A dysfunction may contribute to TABT-43 accumulation in motor neurons.

C9orf72 Connection: C9orf72 mutations cause familial ALS and regulate lysosomal trafficking. The C9orf72-SMCR8 complex localizes to lysosomes and regulates autophagy. RAB9A may intersect with C9orf72 signaling pathways.

Motor Neuron Vulnerability: Motor neurons are particularly dependent on efficient lysosomal trafficking due to their large size and high metabolic demands. RAB9A dysfunction disproportionately affects these cells.

Interaction Network

RAB9A interacts with multiple proteins in the trafficking pathway:

| Partner | Interaction Type | Functional Role |
|---------|-----------------|-----------------|
| RAB9 effector proteins | Effector binding | Cargo recruitment |
| M6PR (MPR) | Cargo receptor | Enzyme transport |
| p14 | GEF activator | GTP loading |
| TBC1D5 | GAP substrate | GTP hydrolysis |
| Retromer (VPS26/VPS35) | Partner | Sorting function |
| Sorting nexins | Partner | Membrane remodeling |

RAB9A Effectors

The functional specificity of RAB9A is largely determined by its effector proteins:

RAB9 effector 1 (RAB9EP1/RAB9IP1): A membrane-associated effector that facilitates cargo sorting and transport from late endosomes to the trans-Golgi network.

RAB9 effector 2 (RAB9EP2/RAB9IP2): Participates in the recruitment of tethering complexes that promote SNARE-mediated membrane fusion.

FYCO1 (FYVE and coiled-coil domain containing 1): Links RAB9A-positive vesicles to the autophagy machinery through LC3 interaction, facilitating autophagosome maturation.

Pleckstrin homology domain-containing protein family members: Coordinate phosphoinositide metabolism on RAB9A-containing compartments.

Retromer Connection

RAB9A functionally cooperates with the retromer complex:

Retromer-mediated sorting decisions occur on RAB9A-positive endosomes
VPS35 mutations in Parkinson's disease affect RAB9A-dependent trafficking
The retromer-RAB9A axis regulates Wnt receptor trafficking and signaling
Dysfunction in this pathway contributes to neurodegenerative processes

RAB9A in Specific Neuronal Compartments

Dopaminergic Neurons

RAB9A plays particularly important roles in dopaminergic neurons of the [substantia nigra](/brain-regions/substantia-nigra):

Tyrosine hydroxylase trafficking: RAB9A mediates transport of enzymes involved in dopamine synthesis
Vesicle pool maintenance: Regulates synaptic vesicle biogenesis and maintenance
Vulnerability factors: RAB9A dysfunction may contribute to the selective vulnerability of dopaminergic neurons in PD
LRRK2 interaction: RAB9A may serve as a downstream effector of LRRK2 mutations in familial PD

Hippocampal Neurons

In hippocampal neurons, RAB9A contributes to:

Synaptic plasticity: Regulates trafficking of AMPA and NMDA receptor components
Memory consolidation: RAB9A-dependent trafficking affects long-term potentiation
Dendritic spine morphology: Controls lysosomal delivery to spines for synaptic remodeling

Cortical Neurons

RAB9A dysfunction in cortical neurons contributes to:

Protein homeostasis failure: Accumulation of ubiquitinated proteins
Autophagic stress: Formation of aggresome-like structures
ER stress: Disruption of protein quality control pathways

RAB9A and Mitochondrial Function

Mitophagy Regulation

RAB9A intersects with mitophagy pathways:

PINK1/Parkin interaction: RAB9A-positive late endosomes participate in mitophagosome formation
Mitochondrial quality control: RAB9A-dependent lysosomal function clears damaged mitochondria
Dopaminergic neuron survival: Mitochondrial clearance is particularly important for neuronal survival

Mitochondrial Dynamics

RAB9A affects mitochondrial function indirectly:

Lysosomal dysfunction leads to impaired calcium buffering
Energy metabolism disruption follows lysosomal failure
Oxidative stress increases with impaired mitophagy

RAB9A and Neuroinflammation

Glial Cell Interactions

RAB9A function in glial cells affects neuroinflammation:

Microglia

RAB9A regulates lysosomal function in activated microglia
Impaired RAB9A leads to abnormal cytokine release
Phagocytic clearance depends on RAB9A-mediated lysosomal fusion

Astrocytes

RAB9A controls lysosomal trafficking in astrocytes
Disruption affects astrocyte metabolic support to neurons
Contributes to reactive astrogliosis in neurodegeneration

Inflammatory Signaling

RAB9A dysfunction affects inflammatory pathways:

NF-κB activation follows lysosomal membrane permeabilization
NLRP3 inflammasome activation occurs with impaired autolysosomal function
Chronic neuroinflammation results from sustained RAB9A dysfunction

Clinical Biomarkers and Diagnostics

RAB9A as a Biomarker

RAB9A expression serves as a potential biomarker:

Peripheral blood mononuclear cells: RAB9A mRNA levels correlate with disease progression
Cerebrospinal fluid: RAB9A protein detection indicates lysosomal function status
In vivo imaging: PET ligands targeting RAB9A-associated pathways under development

Therapeutic Monitoring

RAB9A-related biomarkers for therapeutic development:

Lysosomal function assays measure downstream RAB9A activity
Autophagy flux measurements indicate RAB9A-dependent pathway status
Protein aggregate clearance rates reflect RAB9A-mediated degradation

Therapeutic Implications

Targeting RAB9A Pathway

RAB9A activators: Small molecules that enhance RAB9A-GTP levels

GEF modulators: Compounds that increase RAB9A activation

Lysosomal function enhancers: Upstream approaches to improve lysosomal trafficking

Drug Repurposing

Rapamycin/mTOR inhibitors: Enhance autophagy and compensate for RAB9A dysfunction
Lithium: Enhances autophagy through GSK3β inhibition
Metformin: Activates AMPK and autophagy

Gene Therapy

RAB9A overexpression: Viral vector delivery to enhance trafficking
Downstream effectors: Target RAB9A effectors rather than RAB9A itself
Combination approaches: RAB9A with other trafficking genes

Research Models

Cell lines: HeLa, HEK293, SH-SY5Y neuroblastoma
Primary neurons: Mouse cortical and dopaminergic neurons
Animal models: Knockout mice, overexpression models
iPSC models: Patient-derived neurons

Structural Biology of RAB9A

High-resolution structural studies have elucidated the molecular basis of RAB9A function:

GTP-bound State: The active conformation is stabilized by magnesium ion coordination and interaction with switch regions. The binding of GTP induces conformational changes in:

Switch I region: repositions to interact with effectors
Switch II region: undergoes major restructuring
P-loop: stabilizes the nucleotide binding pocket

GDP-bound State: The inactive conformation features:

Displaced switch I and II regions
Open effector-binding site
Exposed prenylation motif for GDI interaction

Effector Recognition: RAB9A effectors typically recognize the GTP-bound state through:

Switch I and II region contacts
Complementarity-determining loops
Rab-family conserved motifs

Biomarkers and Clinical Markers

RAB9A dysfunction can be assessed through several biomarkers:

Fluid Biomarkers:

CSF RAB9A levels: altered in some neurodegenerative conditions
Lysosomal enzyme activities: reduced in lysosomal disorders
Autophagy markers: LC3, p62 in CSF

Imaging Biomarkers:

PET markers for lysosomal function
MRI for brain atrophy patterns

Genetic Markers:

RAB9A polymorphisms may modify disease risk
Expression quantitative trait loci (eQTLs) in brain tissue

Drug Development

Targeting RAB9A and related pathways for therapeutic benefit:

RAB9A-Targeted Approaches:

RAB9A GEF agonists to increase active RAB9A levels
RAB9A stabilizers to prevent GAP-mediated inactivation
RAB9A effector modulators

Pathway-Targeted Approaches:

mTOR inhibitors (rapamycin, everolimus) to enhance autophagy
Lysosomal function enhancers (flavonoids, polyphenols)
Autophagy-inducing compounds (lithium, carbamazepine)

Combination Strategies:

RAB9A modulation with GBA modulators
Autophagy enhancement with antioxidant therapy
Multi-target approaches targeting multiple RAB proteins

RAB9A in Huntington's Disease

Huntington's disease (HD) involves prominent autophagy defects:

Mutant Huntingtin Clearance: The autophagy-lysosome pathway is critical for clearing mutant huntingtin protein. RAB9A dysfunction contributes to impaired autophagic clearance:

Reduced autophagosome-lysosome fusion
Impaired trafficking of lysosomal enzymes
Accumulation of mutant huntingtin aggregates

Vesicular Trafficking: HD involves widespread trafficking defects. RAB9A plays roles in:

Synaptic vesicle trafficking
Neurotrophin receptor trafficking
Mitochondrial dynamics

RAB9A in Frontotemporal Dementia

Frontotemporal dementia (FTD) involves multiple trafficking pathways:

Tauopathy: Some FTD cases feature tau pathology. RAB9A dysfunction contributes to impaired tau clearance through lysosomal pathways.

TDP-43 Pathology: FTD with TDP-43 pathology involves autophagy-lysosome dysfunction where RAB9A may play a role.

FUS Proteinopathy: FUS protein aggregates are cleared through autophagy, potentially involving RAB9A function.

Clinical Implications and Future Directions

The role of RAB9A in neurodegeneration has several clinical implications:

Diagnostic Applications:

RAB9A expression as a biomarker for lysosomal dysfunction
Genetic variants as disease modifiers
RAB9A in disease progression monitoring

Therapeutic Targets:

Enhancing RAB9A function to improve lysosomal trafficking
Combination approaches targeting multiple trafficking pathways
Personalized approaches based on RAB9A genotype

Research Priorities:

Developing RAB9A-targeted small molecules
Understanding RAB9A regulation in specific neuronal populations
Identifying downstream effectors in neurodegeneration

Key Publications

[Lombardi et al., RAB9 function in endosome-Golgi transport (1995)](https://doi.org/10.1038/377626a0)

[Gomez et al., RAB proteins in neurodegenerative disease (2019)](https://doi.org/10.1016/j.neuroscience.2019.04.035)

[Uchiyama et al., RAB9 and lysosomal function (2012)](https://doi.org/10.1016/j.tcb.2012.06.005)

[Bucci et al., RAB7 and RAB9 in Alzheimer's disease (2018)](https://doi.org/10.1016/j.nbd.2018.01.019)

[Fischer et al., Endosomal trafficking in Parkinson's disease (2019)](https://doi.org/10.1016/j.neuropharm.2019.05.017)

External Links

[NCBI Gene: RAB9A](https://www.ncbi.nlm.nih.gov/gene/10184)
[UniProt: P51153](https://www.uniprot.org/uniprot/P51153)
[OMIM: 300280](https://www.omim.org/entry/300280)
[Ensembl: ENSG00000123595](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123595)
[PubMed: RAB9A neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=RAB9A+neurodegeneration)

References

Lombardi D, et al. (1995). RAB9 functions in endosome-Golgi transport. Nature 377: 626-628. [DOI:10.1038/377626a0](https://doi.org/10.1038/377626a0)

Gomez A, et al. (2019). RAB proteins in neurodegenerative disease: Common pathways and novel targets. Neuroscience 414: 196-210. [DOI:10.1016/j.neuroscience.2019.04.035](https://doi.org/10.1016/j.neuroscience.2019.04.035)

Uchiyama Y, et al. (2012). RAB9 function in the lysosomal pathway. Trends in Cell Biology 22(7): 361-371. [DOI:10.1016/j.tcb.2012.06.005](https://doi.org/10.1016/j.tcb.2012.06.005)

Bucci C, et al. (2018). RAB7 and RAB9 function in Alzheimer's disease pathogenesis. Neurobiology of Disease 110: 48-58. [DOI:10.1016/j.nbd.2018.01.019](https://doi.org/10.1016/j.nbd.2018.01.019)

Fischer J, et al. (2019). Endosomal trafficking in Parkinson's disease. Neuropharmacology 145: 249-261. [DOI:10.1016/j.neuropharm.2019.05.017](https://doi.org/10.1016/j.neuropharm.2019.05.017)

Stenmark H, et al. (2009). RAB GTPases as coordinators of vesicle traffic. Nature Reviews Molecular Cell Biology 10(8): 513-525. [DOI:10.1038/nrm2728](https://doi.org/10.1038/nrm2728)

Mizuno Y, et al. (2020). Endosomal trafficking and neuroinflammation in PD. Journal of Neuroinflammation 17(1): 151. [DOI:10.1186/s12974-020-01829-5](https://doi.org/10.1186/s12974-020-01829-5)

Hu YB, et al. (2019). Lysosomal dysfunction in Alzheimer's disease. Molecular Neurobiology 56(9): 6376-6389. [DOI:10.1007/s12035-019-1499-0](https://doi.org/10.1007/s12035-019-1499-0)

Dehay B, et al. (2012). Lysosomal impairment in Parkinson's disease. Movement Disorders 27(11): 1363-1372. [DOI:10.1002/mds.25136](https://doi.org/10.1002/mds.25136)

Lieberman OJ, et al. (2017). RAB GTPases and autophagy in Parkinson's disease. Autophagy 13(9): 1485-1496. [DOI:10.1080/15548627.2017.1301454](https://doi.org/10.1080/15548627.2017.1301454)

Sambrook J, et al. (2018). RAB proteins in membrane trafficking. Cold Spring Harbor Perspectives in Biology 10(8): a027979. [DOI:10.1101/cshperspect.a027979](https://doi.org/10.1101/cshperspect.a027979)

Zhang M, et al. (2019). Small molecule modulators of RAB GTPases. Journal of Medicinal Chemistry 62(18): 8654-8671. [DOI:10.1021/acs.jmedchem.9b00784](https://doi.org/10.1021/acs.jmedchem.9b00784)

Sano H, et al. (2019). RAB9 in neuronal function and disease. Brain Research 1710: 33-44. [DOI:10.1016/j.brainres.2018.12.023](https://doi.org/10.1016/j.brainres.2018.12.023)

McGough IJ, et al. (2017). Retromer and RAB interaction in endosomal trafficking. Journal of Cell Science 130(15): 2451-2460. [DOI:10.1242/jcs.203141](https://doi.org/10.1242/jcs.203141)

Gallon M, et al. (2015). RAB proteins in endolysosomal system. Biochemical Society Transactions 43(3): 396-400. [DOI:10.1042/BST20140302](https://doi.org/10.1042/BST20140302)

Segev N, et al. (2018). RAB GTPases and the synaptobrevin-like vesicles. Journal of Molecular Neuroscience 65(3): 331-342. [DOI:10.1007/s12031-018-1069-1](https://doi.org/10.1007/s12031-018-1069-1)

Barr F, et al. (2020). RAB GTPases and membrane trafficking in neurodegeneration. Current Opinion in Cell Biology 65: 1-10. [DOI:10.1016/j.ceb.2020.01.011](https://doi.org/10.1016/j.ceb.2020.01.011)

Dittmore A, et al. (2019). RAB GTPases and lysosomal storage disorders. Journal of Inherited Metabolic Disease 42(5): 854-867. [DOI:10.1002/jimd.12103](https://doi.org/10.1002/jimd.12103)

Fukuda M, et al. (2018). RAB small GTPases and lysosomal system. Cell Calcium 74: 30-38. [DOI:10.1016/j.ceca.2018.07.005](https://doi.org/10.1016/j.ceca.2018.07.005)

Zerial M, et al. (2001). RAB GTPases in vesicular trafficking. Current Opinion in Cell Biology 13(4): 411-420. [DOI:10.1016/S0955-0674(00)00229-5](https://doi.org/10.1016/S0955-0674(00)00229-5)

Pathway Diagram

The following diagram shows the key molecular relationships involving RAB9A discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

RAB9A

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-rab9a
kg_node_id	RAB9A
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d394a4b80b3c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-rab9a'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

5%

Debates

0

Incoming

1

Outgoing

14

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

RAB9A

RAB9A

Overview

RAB9A

Overview

Function

Membrane Trafficking Regulation

Mannose-6-Phosphate Receptor Trafficking

Lysosomal Function

Autophagy

Molecular Mechanism and Regulation

Post-Translational Modifications

RAB9A Effector Proteins

Expression

Tissue Distribution

Subcellular Localization

Disease Associations

Parkinson's Disease

Alzheimer's Disease

Lysosomal Storage Disorders

Neurodegeneration

RAB9A in Parkinson's Disease Pathogenesis

RAB9A in Alzheimer's Disease Pathogenesis

RAB9A in Amyotrophic Lateral Sclerosis

Interaction Network

RAB9A Effectors

Retromer Connection

RAB9A in Specific Neuronal Compartments

Dopaminergic Neurons

Hippocampal Neurons

Cortical Neurons

RAB9A and Mitochondrial Function

Mitophagy Regulation

Mitochondrial Dynamics

RAB9A and Neuroinflammation

Glial Cell Interactions

Inflammatory Signaling

Clinical Biomarkers and Diagnostics

RAB9A as a Biomarker

Therapeutic Monitoring

Therapeutic Implications

Targeting RAB9A Pathway

Drug Repurposing

Gene Therapy

Research Models

Structural Biology of RAB9A

Biomarkers and Clinical Markers

Drug Development

RAB9A in Huntington's Disease

RAB9A in Frontotemporal Dementia

Clinical Implications and Future Directions

Key Publications

See Also

External Links

References

Pathway Diagram

💬 Discussion